Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cullinan Management ( (CGEM) ) has provided an announcement.
On November 18, 2025, Cullinan Amber Corp., a subsidiary of Cullinan Therapeutics, Inc., decided to cease further development of its cancer immunotherapy product, CLN-617. Consequently, the company notified MIT of its decision to terminate the Exclusive Patent License Agreement, effective February 18, 2026, and will return the licensed patent rights to MIT.
The most recent analyst rating on (CGEM) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Cullinan Management stock, see the CGEM Stock Forecast page.
Spark’s Take on CGEM Stock
According to Spark, TipRanks’ AI Analyst, CGEM is a Underperform.
Cullinan Management’s stock is facing significant challenges primarily due to its weak financial performance, characterized by persistent losses and negative cash flow. The technical analysis provides some short-term optimism, but the overall technical outlook remains bearish. The valuation is unattractive due to a negative P/E ratio and no dividend yield, indicating high risk for investors. The stock’s potential is heavily reliant on strategic changes and improved financial health.
To see Spark’s full report on CGEM stock, click here.
More about Cullinan Management
Cullinan Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative cancer therapies. Its subsidiary, Cullinan Amber Corp., was involved in developing a cancer immunotherapy product, CLN-617, under an exclusive patent license from MIT.
Average Trading Volume: 956,604
Technical Sentiment Signal: Hold
Current Market Cap: $499.2M
For detailed information about CGEM stock, go to TipRanks’ Stock Analysis page.